Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advagraf versus Prograf pharmacokinetics in primary solid organ transplantation
2010-019859-21Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tacrolimus in Transplant rejection prophylaxis, Lung allograft rejection (LAR), Cardiac Rejection and 2 more (2 arms), sponsored by Astellas Pharma. Primary endpoint: Tacrolimus AUC0-24h after first dose and repeated administration. Started Jan 2011; status: completed.
02
Drugs
tacrolimus
03
Conditions
Transplant rejection prophylaxisLung allograft rejection (LAR)Cardiac RejectionPancreas Allograft Rejectiongraft rejection
Beyond the preview
Go deeper on 2010-019859-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019859-21.